In this study, we demonstrate that combinatorial treatment with anti-PD-1 or anti-PD-L1 blocking mAb and non-replicative Ad5-CMV-mTNFα/mIL-2 improves the anti-tumor activity of the intratumoral immune compartment in the context of HNSCC. This evidence concerns the gene CD274 and neoplasm.